/주식/THTX
THTX

THTX

USD

Theratechnologies Inc. Common Shares

$2.770-0.020 (-0.717%)

실시간 가격

Healthcare
생명공학
캐나다

가격 차트

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$2.790

고가

$2.900

저가

$2.725

거래량

0.04M

기업 기본 정보

시가총액

129.6M

산업

생명공학

국가

Canada

거래 통계

평균 거래량

3.06M

거래소

NCM

통화

USD

52주 범위

저가 $1.08현재가 $2.770고가 $3.13

관련 뉴스

GlobeNewswire

Theratechnologies Provides Update on Sale Process

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced that following careful

더 보기
Theratechnologies Provides Update on Sale Process
BusinessWire

Soleus Capital Issues Letter to The Board of Theratechnologies

Soleus Capital Management, L.P. ("Soleus Capital"), a healthcare investment firm which owns in excess of 10% of the stock of Theratechnologies Inc. (NASDAQ:THTX) (the "Company"), today sent a letter to the Board of

더 보기
Soleus Capital Issues Letter to The Board of Theratechnologies
GlobeNewswire

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in

더 보기
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
BusinessWire

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

Future Pak, LLC ("Future Pak") today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratechnologies Inc. ("Theratechnologies") (NASDAQ:THTX).

더 보기
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
GlobeNewswire

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval

더 보기
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
GlobeNewswire

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report